Meeting
2022 ASCO Genitourinary Cancers Symposium
Incidence and clinical outcomes of HER2-altered bladder cancer (BC) patients (pts).
Authors
Michael Lattanzi
Memorial Sloan Kettering Cancer Center, New York, NY
Michael Lattanzi , Andrew Niederhausern , Junting Zheng , Nadia Bahadur , Chelsea Nichols , Laura Barton , Fenil Gandhi , Kimberly Chan , Alysha Insinga , John Philip , Theodora Bakker , Ashley Marie Regazzi , Brendan John Guercio , Min Yuen Teo , David Henry Aggen , Eugene J. Pietzak , David B. Solit , Irina Ostrovnaya , Neil J. Shah , Gopa Iyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 556)
DOI
10.1200/JCO.2022.40.6_suppl.556
Abstract #
556
Poster Bd #
J12
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors.
First Author: Dazhi Liu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Clinicopathological features and clinical outcomes in individuals with Krukenberg tumors of colorectal origin.
First Author: Colin P Bergstrom
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Characterizing outcomes of ERBB2-amplified biliary tract cancer.
First Author: Daniel Aaron Fox
Poster
2023 ASCO Annual Meeting
ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.
First Author: Arielle J Medford